2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12090R
    Anacetrapib (Standard) 875446-37-0 98%
    Anacetrapib (Standard) is the analytical standard of Anacetrapib. This product is intended for research and analytical applications. Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
    Anacetrapib (Standard)
  • HY-121005
    Bufetolol 53684-49-4 98%
    Bufetolol is an inhibitor for β-adrenergic receptor, that affects the maximum velocity of rise of the action potential, and exhibits antiarrhythmic efficacy.
    Bufetolol
  • HY-121019
    Flordipine 77590-96-6 98%
    Floripine is an orally active calcium antagonist with anti hypertensive activity.
    Flordipine
  • HY-121180
    A-58365B 87896-53-5 98%
    A-58365B is an Angiotensin-converting Enzyme (ACE) inhibitor. A-58365B has antihypertensive effects.
    A-58365B
  • HY-121214
    Amisulbrom 348635-87-0 99.92%
    Amisulbrom is a sulfonamide fungicide used to control oomycete diseases. Amisulbrom inhibits the cytochrome-bc1 complex of the mitochondrial electron transport system.
    Amisulbrom
  • HY-121244
    Coumafuryl 117-52-2 98%
    Coumafuryl is a kind of coumarin rodenticide. Coumafuryl inhibits the metabolic cycle of vitamin K that causes the interference with protein biosynthesis of vitamin K-dependent coagulant factors (II, VII, IX, and X factors) in the liver.
    Coumafuryl
  • HY-12136R
    Purpurogallin (Standard) 569-77-7
    Purpurogallin (Standard) is the analytical standard of Purpurogallin. This product is intended for research and analytical applications. Purpurogallin is a naturally phenol extracted from the plants of Quercus spp, has potent xanthine oxidase (XO) inhibitory activity with an IC50 of 0.2 μM. Purpurogallin has antioxidant and anti-inflammatory effects.
    Purpurogallin (Standard)
  • HY-121448
    GW409544 258345-41-4 98%
    GW409544 is a potent PPARα and PPARγ activator, with EC50 values of 2.3 nM and 0.28 nM for PPARα and PPARγ, respectively. GW409544 can be used for the research of metabolic and cardiovascular diseases.
    GW409544
  • HY-121453
    Bamifylline hydrochloride 20684-06-4 98%
    Bamifylline hydrochloride is a drug in the chemical class of xanthine that acts as a selective adenosine A1 receptor antagonist.
    Bamifylline hydrochloride
  • HY-121573
    α-Acetyldigoxin 5511-98-8 98%
    α-Acetyldigoxin can be used in heart failure related research and is orally available. The bioavailability of α-Acetyldigoxin is lower than that of β-Acetyldigoxin when administered orally and intravenously.
    α-Acetyldigoxin
  • HY-121701
    SR33805 analog 121346-32-5 98%
    SR 33805 (analog) is an orally active Ca2+ channel blocker that selectively inhibits the proliferation of smooth muscle cells. SR 33805 (analog) reduces calcium uptake by blocking calcium channels, thereby inhibiting smooth muscle cell proliferation induced by serum, platelet-derived growth factor, and basic fibroblast growth factor. SR 33805 (analog) significantly reduces intimal thickening following endothelial injury in rabbits. SR 33805 (analog) shows promise for cardiovascular disease research, such as in early atherosclerosis.
    SR33805 analog
  • HY-121720
    L 657925 122757-59-9 98%
    L 657925 is a potent thromboxane A2 (TXA2) antagonist. L 657925 selectively abolishes ONO 11113-evoked transient increment in [Ca22+].
    L 657925
  • HY-121762
    NTE-122 dihydrochloride 166967-84-6 98%
    NTE-122 (dihydrochloride) is an inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), with the IC50 in liver and aorta of cholesterol-fed rabbits of 7.6nM, 4.4nM and 9.6 nM, respectively, that plays an important role in atherosclerosis.
    NTE-122 dihydrochloride
  • HY-12176R
    Aliskiren (Standard) 173334-57-1 98%
    Aliskiren (Standard) is the analytical standard of Aliskiren. This product is intended for research and analytical applications. Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
    Aliskiren (Standard)
  • HY-12177R
    Aliskiren hemifumarate (Standard) 173334-58-2 98%
    Aliskiren (hemifumarate) (Standard) is the analytical standard of Aliskiren (hemifumarate). This product is intended for research and analytical applications. Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
    Aliskiren hemifumarate (Standard)
  • HY-122032
    A 58365A 87896-52-4 98%
    A 58365A is a potent angiotensin converting enzyme (ACE) inhibitor.
    A 58365A
  • HY-122126
    BN 52111 120889-14-7 98%
    BN 52111 is a potent platelet-activating factor (PAF) receptor antagonist.
    BN 52111
  • HY-122149
    L-648051 91541-18-3 98%
    L-648051 is a leukotriene D4 receptor (LTD4) antagonist. L-648051 plays an important role in arrhythmias.
    L-648051
  • HY-122212
    PF-9404C 780825-97-0 98%
    PF-9404C is a potent beta-adrenergic blocker and a vasorelaxing agent. PF-9404C can be used as NO-donor. PF-9404C shows antihypertensive and cardioprotective action.
    PF-9404C
  • HY-122237
    ATZ-1993 219705-77-8 98%
    ATZ-1993 is an orally active, nonpeptide endothelin receptor subtype Aand endothelin receptor subtype B antagonist with pKi values of 8.69, 7.20, respectively. ATZ-1993 has the potential for the research of intimal hyperplasia after balloon denudation of the carotid artery.
    ATZ-1993
Cat. No. Product Name / Synonyms Application Reactivity